logo
  • About us
    • In brief
    • The Board of Directors
    • Management Team
    • Corporate Governance
    • Intellectual Properties
    • Partnerships
    • Environment & quality
    • Organization
    • Career
  • Project portfolio
    • Project overview
    • Research areas
    • Development phases
    • Publications
  • Contract research
    • Autoradiography
    • Pharmacokinetics
    • Analytical chemistry
    • Disease models
  • Investor info
    • Contacts
    • Press releases
    • Stock
    • Interim reports
    • Annual reports
    • Presentations
    • Ownership
    • Official documents
    • Calendar
  • Press & news
    • Press releases
    • Interim reports
    • Annual reports
    • Features
    • Image bank
    • Calendar
    • Contacts
  • Contact
    • Visit us
rss RSS
font size decrease font increase font

Active Biotech develops innovative pharmaceuticals that modulate the body's own immune system.
We focus on widespread diseases for which a tremendous need is felt for new and more effective treatments.

  • 2013-05-16 New data to be presented at the 2013 ASCO Annual Meeting show Active Biotech's commitment to oncology research
  • 2013-05-16 Annual General Meeting of Active Biotech AB
  • 2013-04-25 Active Biotech AB Interim Report January - March 2013
  • 2013-04-25 Active Biotech and Ipsen update the analysis plan for the 10TASQ10 trial evaluating tasquinimod in the treatment of prostate cancer
  • 2013-04-15 Annual Report 2012 Active Biotech AB (publ)

Annual General Meeting - May 15, 2013

Annual Report 2012

Subscribe to press releases from Active Biotech

Read more >>
Active Biotech AB, Scheelevägen 22, P.O. Box 724, SE-220 07 Lund, Sweden, Telephone +46 46 19 20 00